All In Biotech

Drug Trial Radar · NCT05586074

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

324

Planned (sponsor's estimate)

Start

Mar 3, 2023

Primary completion

Nov 30, 2027

Study completion May 30, 2028

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized,multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.

Conditions

  • Leukemia, Acute Myeloid (AML)

Interventions

  • ClifutinibDrug

    tablet, oral

  • LoDACDrug

    subcutaneous (SC) or intravenous (IV) injection

  • AzacitidineDrug

    SC or IV

  • DecitabineDrug

    IV

  • Ara-C±IDADrug

    SC and IV

  • FLAG-IDADrug

    SC and IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OSTime frame: From the date of randomization until the date of death from any cause, assessed up to 5 years
  2. CR/CRh rateTime frame: From randomization until the data cut-off date of April 2025, all subjects included in the primary analysis of CR/CRh rate were followed up at least 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • the First Affiliated Hospital,College of Medicine,Zhejiang University

    Hanzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.